Market Research Logo

Global Age-related Macular Degeneration Market 2016-2020

Global Age-related Macular Degeneration Market 2016-2020

About AMD

AMD is the degeneration or disintegration of the eye's macula. The macula is a small area of the retina that is responsible for the central vision. AMD can be classified into two types: dry and wet macular degenerations. When the tiny abnormal blood vessels begin growing toward the macula, it develops into wet AMD. Dry AMD occurs when small, yellowish deposits called drusen start accumulating beneath the macula. While some treatments are available for wet AMD; there is no treatment available at the moment for dry AMD.

Technavio’s analysts forecast the global age-related macular degeneration (AMD) market to grow at a CAGR of 7.37% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global age-related macular degeneration (AMD) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of AMD.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Age-Related Macular Degeneration (AMD) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bayer HealthCare
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
Other prominent vendors
  • Alcon
  • Allergan
  • Adverum Biotechnologies
  • Bausch + Lomb
  • Gilead Sciences
  • Iconic Therapeutics
  • Lpath
  • Neurotech Pharmaceuticals
  • Ohr Pharmaceutical
  • Opthea
  • Ophthotech
  • PanOptica
  • Pfizer
  • Promedior
  • QLT
  • Quark
  • Resolvyx Pharmaceuticals
  • RXi Pharmaceuticals
  • Sagent Pharmaceuticals
  • Santen Pharmaceuticals
  • Sanwa Kagaku Kenkyusho
Market driver
  • Increasing reimbursement benefits for AMD drugs
  • For a full, detailed list, view our report
Market challenge
  • Availability of alternative therapies
  • For a full, detailed list, view our report
Market trend
  • Novel treatment approaches for developing AMD drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Age-Related Macular Degeneration (AMD) Market 2016-2020

Technavio recognizes the following companies as the key players in the global age-related macular degeneration (AMD) market: Bayer HealthCare, F. Hoffmann-La Roche, Novartis, and Regeneron Pharmaceuticals.

Other Prominent Vendors in the market are: Alcon, Allergan, Adverum Biotechnologies, Bausch + Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech, PanOptica, Pfizer, Promedior , QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen Pharmaceuticals, and Sanwa Kagaku Kenkyusho.

Commenting on the report, an analyst from Technavio’s team said: “The AMD market is experiencing a shift toward combination products, using two or more effective treatments. Parallel with the introduction of novel, potent monotherapies for AMD, the market is facing a clear trend toward individualized medicine. The shortcomings of treatment with a single drug can overcome with the use of combination therapy. With AMD, this may mean combination therapy. The need for practical combination therapy exists to address these shortcomings of monotherapy. The goal of combination therapy is to disrupt the multiple stimuli that lead to pathologic cellular proliferation.”

According to the report, one of the key drivers for market growth will be increasing reimbursement benefits for AMD drugs. Medicare creates a national reimbursement rate depends on the average selling price of the drug. In this case, the agency pays approximately almost 80% of the ranibizumab and bevacizumab injection, leaving 20% of the drug cost to be co-paid. Medicare Part B (insurance) also covers specific diagnostic tests and treatment of conditions and diseases of the eye, including treatment with specific injected drugs.

Further, the report states that the lack of trained ophthalmologists who have expertise in treating eye disorders such as AMD is one of the key challenges in the market. Although the number of people diagnosed with or prone to eyesight disorders has been on the rise every year, there are not enough trained and experienced eye care professionals (ophthalmologists, optometrists, ophthalmic assistants, and ophthalmic nurses) to treat eye disorders. For instance, in Europe, there is just one ophthalmologist for every 8,000 people. The situation is worse in low- and middle-income countries such as India, where there is just one ophthalmologist for every 200,000 people. This poses a significant challenge to the growth of the market.

Companies Mentioned

Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Adverum Biotechnologies, Bausch + Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech, PanOptica, Pfizer, Promedior , QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen Pharmaceuticals, and Sanwa Kagaku Kenkyusho.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Leading drugs for AMD
      • Table Novel opportunities for AMD market: Entry of squalamine
      • Table Global AMD market snapshot
  • Key buying criteria
    • Table Key buying criteria for AMD drugs
    • Table Key buying criteria for global AMD market 2015
    • Table Impact of key customer segments on global AMD market 2015
  • AMD: Overview
    • Understanding the disease
    • Stages of AMD
      • Table Stages of AMD
    • Etiology
      • Table Risk factors for AMD
    • Signs and symptoms
    • Diagnosis
      • Table Diagnosis of AMD
    • Management
      • Table Product portfolio of current AMD therapies
  • Pipeline portfolio
    • Table Share of pipeline molecules in global AMD market
  • Market landscape
    • Market overview
      • Table Prevalence of AMD 2000 and 2050 (millions)
      • Table Global AMD market snapshot: Developed and emerging markets 2015
      • Table Factors influencing the global AMD market 2015
      • Table Global AMD market 2015-2020 ($ billions)
      • Table Impact of drivers and challenges of global AMD market
      • Table Opportunity analysis of global AMD market by type
  • Market analysis of major drugs
    • Lucentis
      • Table Timeline of key regulatory approvals of Lucentis
      • Table YoY growth and revenue generated from sales of Lucentis 2013-2015 ($ billions)
    • Eylea
      • Table Timeline of key regulatory approvals and filings of Eylea
      • Table YoY revenue and growth rate of Eylea 2012-2015 ($ billions)
    • Avastin
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type
    • Table Global AMD market: Segmentation by type 2015-2020
    • Table Global AMD market segmentation: Growth cycle analysis
    • Global wet AMD market
    • Market overview
      • Table Competitive landscape of wet AMD drugs
      • Table Global wet AMD market 2015-2020 ($ billions)
    • Global dry AMD market
    • Market overview
      • Table Opportunity analysis of global dry AMD market
      • Table Global dry AMD market 2015-2020 ($ millions)
  • Market segmentation by ROA
    • Table Segmentation of global AMD market by ROA 2015
    • IV
    • Intravitreal
  • Geographical segmentation
    • Table Global AMD market: Geographical outlook (2015-2020)
    • Table Global AMD market: Geography outlook 2015
    • Table Revenue/growth outlook in different countries/regions 2015
    • Table Global AMD market segmentation by region: Market growth lifecycle analysis 2015
    • Table AMD market revenue by geography 2015-2020 ($ billions)
    • AMD market in Americas
      • Table Opportunity analysis of AMD market in Americas
      • Table AMD market in Americas 2015-2020 ($ billions)
    • AMD market in EMEA
      • Table Opportunity analysis of AMD market in EMEA
      • Table AMD market in EMEA 2015-2020 ($ billions)
    • AMD market in APAC
      • Table Opportunity analysis of AMD market in APAC
      • Table Prevalence rates of AMD in APAC countries 2015
      • Table AMD market in APAC 2015-2020 ($ billions)
  • Market drivers
    • Increase in aging population
      • Table Percentage of Americans with vision loss
      • Table Distribution of population aged 60 years and over (millions)
    • Increasing reimbursement benefits for AMD drugs
    • Increase in diagnosis rate
    • High patient and physician satisfaction
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Gap in patient demand vs. ophthalmology expert supply
    • Increasing use of off-label drugs
    • Availability of alternative therapies
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Novel treatment approaches for developing AMD drugs
    • Increased research grants, initiatives, and programs
    • Use of combination therapies
  • Vendor landscape
    • Competitive scenario
      • Table Geographical presence of key vendors
      • Table Company portfolio analysis in global AMD market 2016-2020
    • Other prominent vendors
  • Key vendor analysis
    • Bayer HealthCare
      • Table Bayer HealthCare: Profile
      • Table Bayer HealthCare: Metrics analysis
      • Table Bayer HealthCare: Growth strategy matrix
      • Table Bayer HealthCare: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Profile
      • Table F. Hoffmann-La Roche: Metrics analysis
      • Table F. Hoffmann-La Roche: Growth strategy matrix
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • Novartis
      • Table Novartis: Specialty ophthalmic segmentation by revenue 2015
      • Table Novartis: Profile
      • Table Novartis: Metrics analysis
      • Table Novartis: Growth strategy matrix
      • Table Novartis: Opportunity assessment
    • Regeneron Pharmaceuticals
      • Table Regeneron Pharmaceuticals: Profile
      • Table Regeneron Pharmaceuticals: Metrics analysis
      • Table Regeneron Pharmaceuticals: Growth strategy matrix
      • Table Regeneron Pharmaceuticals: Growth opportunity assessment
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report